| Outcome Measures: |
Primary: Pharmacokinetics (PK) of Triferic Iron Administered Via Hemodialysate in Adult CKD-5HD Patients: Cmax., The PK will be done by assessing the mean Cmax of total serum iron from Triferic administered via hemodialysate, compared to Triferic administered at a fixed IV dose of 6.6 mg iron/kg during a single dialysis session., 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours|Pharmacokinetics (PK) of Triferic Iron Administered IV in Adult CKD-5HD Patients: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantified Concentration (AUC(Last))., The PK will be done by assessing the mean area under the serum concentration-time curve from time zero to the time of the last quantified concentration (AUC(last)) and comparing between Triferic administered via hemodialysate and Triferic administered at a fixed IV dose of 6.6 mg iron/kg (pre-dialyzer and post-dialyzer) during a single dialysis session., 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours | Secondary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Safety will be documented by recording the incidence of treatment-emergent adverse events (TEAEs), 13 days|Number of Participants With Treatment-emergent Serious Adverse Events (TEAEs), Safety will be documented by recording the incidence of treatment-emergent serious adverse events (TESAEs), 13 days
|
